von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 2007 Dec;6(12):967-74
The threat of a major human influenza pandemic, in particular from highly aggressive strains such as avian H5N1, has emphasized the need for therapeutic strategies to combat these pathogens. At present, two inhibitors of sialidase (also known as neuraminidase), a viral enzyme that has a key role in the life cycle of influenza viruses, would be the mainstay of pharmacological strategies in the event of such a pandemic. This article provides a historical perspective on the discovery and development of these drugs - zanamivir and oseltamivir - and highlights the value of structure-based drug design in this process.
See Also:
Latest articles in those days:
- Surveillance for highly pathogenic avian influenza A (H5N1) in a raptor rehabilitation center-2022 2 days ago
- [preprint]Detection of hemagglutinin H5 influenza A virus sequence in municipal wastewater solids at wastewater treatment plants with increases in influenza A in spring, 2024 2 days ago
- Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Domestic Dairy Cattle and Cats, United States, 2024 2 days ago
- Latest developments in early diagnosis and specific treatment of severe influenza infection 3 days ago
- Factors affecting highly pathogenic avian influenza vaccination practices at poultry farms in Tra Vinh, Vietnam 3 days ago
[Go Top] [Close Window]